Hikma Pharmaceuticals PLC
SWB:H5P
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hikma Pharmaceuticals PLC
SWB:H5P
|
UK |
|
S
|
Sixt SE
DUS:SIX3
|
DE |
|
Guangzhou R&F Properties Co Ltd
OTC:GZUHF
|
CN |
|
Foraco International SA
F:3F3
|
FR |
|
BeOne Medicines AG
SSE:688235
|
CH |
|
D
|
Discovery Silver Corp
TSX:DSV
|
CA |
|
C
|
China Eastern Airlines Corp Ltd
HKEX:670
|
CN |
Dividends
Dividend Yield
Hikma Pharmaceuticals PLC
| Current Yield | |
| Min Yield | |
| Max Yield | |
| Average Yield | |
| Median Yield |
Dividend Per Share
Hikma Pharmaceuticals PLC
H5P have increased by 83%.
Payout Ratio
Hikma Pharmaceuticals PLC
Peers Comparison
Dividends
Shareholder Yield
Current shareholder yield for H5P is
hidden
.
Peers Comparison
Shareholder Yield
Buybacks
Buyback Yield measures how much a company reduces its outstanding shares through repurchases, expressed as a percentage.
This metric directly reflects the company’s efforts to return value to shareholders. By reducing the number of shares, buybacks can increase earnings per share and potentially boost the stock's price.
Peers Comparison
Buybacks
Debt Paydown
Debt Paydown Yield measures the amount of debt a company repays within a specific period, shown as a percentage of its market capitalization.
This metric indicates how the company is using its capital to decrease financial liabilities, which can strengthen its financial health and potentially enhance shareholder value.
Peers Comparison
Debt Paydown
Price Appreciation
H5P Price
Hikma Pharmaceuticals PLC
| Average Annual Return | -2.21% |
| Standard Deviation of Annual Returns | 24.65% |
| Max Drawdown | -53% |
| Market Capitalization | 3.5B EUR |
| Shares Outstanding | 221 886 000 |
| Percentage of Shares Shorted |
N/A
|
